Welcome to our dedicated page for Novocure news (Ticker: NVCR), a resource for investors and traders seeking the latest updates and insights on Novocure stock.
NovoCure Limited develops and commercializes Tumor Treating Fields therapy for solid tumors through wearable medical devices including Optune Gio, Optune Lua and Optune Pax. News about NVCR centers on product approvals, reimbursement decisions, launch activity and the use of TTFields in glioblastoma, pancreatic cancer, non-small cell lung cancer and pleural mesothelioma.
Company updates also cover clinical programs such as PANOVA, LUNAR and KEYNOTE studies, quarterly financial results, research and clinical-study spending, and commercialization across the United States, Europe, Japan and other markets where the company has approved products.
Novocure (NASDAQ:NVCR) announced pricing for $500 million of 0% Convertible Senior Notes due 2025, aiming to close the offering on November 5, 2020. The notes have an initial conversion rate of 5.9439 shares per $1,000 principal, with a conversion price of about $168.24, representing a 50% premium over its stock price on November 2, 2020. Net proceeds of approximately $485.5 million will enhance clinical programs and support general corporate purposes. Noteholders can convert under specific conditions until 2025, while Novocure retains redemption rights under certain scenarios.
Novocure (NASDAQ: NVCR) announced plans to offer $500 million in Convertible Senior Notes due 2025 in a private placement for qualified institutional buyers. An additional $75 million may be offered if the initial purchasers exercise their option within 13 days. Proceeds will support clinical and product development, general corporate purposes, and related activities. The notes will be unsecured and convertible into cash, Novocure's shares, or both. The offering is subject to market conditions, with no guarantee of completion.
Novocure (NASDAQ: NVCR) reported a significant financial performance for Q3 2020, achieving net revenues of $132.7 million, up 44% year-over-year. Gross profit rose to $104.3 million, marking a 51% increase. The net income was $9.3 million, a staggering 381% increase compared to Q3 2019. Active patients grew to 3,361, while Adjusted EBITDA surged 85% to $37.3 million. The company continues to enhance its clinical focus, anticipating key trial data releases in 2021 and 2022, solidifying its position in the oncology market.
Novocure (NASDAQ: NVCR) has formed a strategic alliance with NYU Grossman School of Medicine’s Department of Radiation Oncology to advance the development of Tumor Treating Fields, a therapy utilizing electric fields to disrupt cancer cell division. This partnership aims to establish NYU as a research center for Tumor Treating Fields, facilitating clinical trials and studying its effects in conjunction with radiation therapy and pharmacological agents. The collaboration represents a significant step toward enhancing treatment strategies for aggressive cancers.
Novocure (NASDAQ: NVCR) will report its third quarter 2020 financial results on October 29, 2020, before U.S. markets open. A conference call will discuss results for the three and nine months ending September 30, 2020, at 8 a.m. EDT on the same day. Investors can join via phone at 855-442-6895 for domestic and 509-960-9037 for international. The call will be accessible on Novocure’s Investor Relations page for at least 14 days post-call. The company aims to provide transparent updates on its innovative therapy and ongoing clinical trials.
Novocure (NASDAQ: NVCR) will host a virtual Research & Development Day on November 12, 2020, from 7:30 a.m. to 9:30 a.m. EDT. This event aims to showcase advancements in its clinical and product development pipelines, featuring presentations from Novocure's research teams and prominent scientists focused on Tumor Treating Fields. Attendees can access the live webcast on Novocure's Investor Relations page, with a replay available for 14 days afterward. Novocure is dedicated to treating aggressive cancers through innovative therapies, including ongoing trials for various cancer types.